Emerging Infectious Diseases (May 2022)

Pertactin-Deficient Bordetella pertussis with Unusual Mechanism of Pertactin Disruption, Spain, 1986–2018

  • Alba Mir-Cros,
  • Albert Moreno-Mingorance,
  • M. Teresa Martín-Gómez,
  • Raquel Abad,
  • Iván Bloise,
  • Magda Campins,
  • Alejandro González-Praetorius,
  • M. Nieves Gutiérrez,
  • Héctor Martín-González,
  • Carmen Muñoz-Almagro,
  • M. Ángeles Orellana,
  • Manuela de Pablos,
  • Josep Roca-Grande,
  • Carlos Rodrigo,
  • M. Elena Rodríguez,
  • Sonia Uriona,
  • M. José Vidal,
  • Tomàs Pumarola,
  • M. Nieves Larrosa,
  • Juan José González-López

DOI
https://doi.org/10.3201/eid2805.211958
Journal volume & issue
Vol. 28, no. 5
pp. 967 – 976

Abstract

Read online

Bordetella pertussis not expressing pertactin has increased in countries using acellular pertussis vaccines (ACV). The deficiency is mostly caused by pertactin gene disruption by IS481. To assess the effect of the transition from whole-cell vaccine to ACV on the emergence of B. pertussis not expressing pertactin in Spain, we studied 342 isolates collected during 1986–2018. We identified 93 pertactin-deficient isolates. All were detected after introduction of ACV and represented 38% of isolates collected during the ACV period; 58.1% belonged to a genetic cluster of isolates carrying the unusual prn::del(–292, 1340) mutation. Pertactin inactivation by IS481 insertion was identified in 23.7% of pertactin-deficient isolates, arising independently multiple times and in different phylogenetic branches. Our findings support the emergence and dissemination of a cluster of B. pertussis with an infrequent mechanism of pertactin disruption in Spain, probably resulting from introduction of ACV.

Keywords